Literature DB >> 22041326

Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.

Ewa A Jankowska1, Piotr Rozentryt, Agnieszka Witkowska, Jolanta Nowak, Oliver Hartmann, Beata Ponikowska, Ludmila Borodulin-Nadzieja, Stephan von Haehling, Wolfram Doehner, Waldemar Banasiak, Lech Polonski, Gerasimos Filippatos, Stefan D Anker, Piotr Ponikowski.   

Abstract

BACKGROUND: Iron is an indispensable element of hemoglobin, myoglobin, and cytochromes, and, beyond erythropoiesis, is involved in oxidative metabolism and cellular energetics. Hence, iron deficiency (ID) is anticipated to limit exercise capacity. We investigated whether ID predicted exercise intolerance in patients with systolic chronic heart failure (CHF). METHODS AND
RESULTS: We prospectively studied 443 patients with stable systolic CHF (age 54 ± 10 years, males 90%, ejection fraction 26 ± 7%, New York Heart Association Class I/II/III/IV 49/188/180/26). ID was defined as: serum ferritin <100 μg/L or serum ferritin 100-300 μg/L with serum transferrin saturation <20%. Exercise capacity was expressed as peak oxygen consumption (VO(2)) and ventilatory response to exercise (VE-VCO(2) slope). ID was present in 35 ± 4% (±95% confidence interval) of patients with systolic CHF. Those with ID had reduced peak VO(2) and increased VE-VCO(2) slope as compared to subjects without ID (peak VO(2): 13.3 ± 4.0 versus 15.3 ± 4.5 mL•min•kg, VE-VCO(2) slope: 50.9 ± 15.8 versus 43.1 ± 11.1, respectively, both P < .001, P < .05). In multivariable models, the presence of ID was associated with reduced peak VO(2) (β = -0.14, P < .01 P < .05) and higher VE-VCO(2) slope (β = 0.14, P < .01 P < .05), adjusted for demographics and clinical variables. Analogous associations were found between serum ferritin, and both peak VO(2) and VE-VCO(2) slope (P < .05).
CONCLUSIONS: ID independently predicts exercise intolerance in patients with systolic CHF, but the strength of these associations is relatively weak. Whether iron supplementation would improve exercise capacity in iron-deficient subjects requires further studies. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041326     DOI: 10.1016/j.cardfail.2011.08.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  61 in total

Review 1.  Transition metals and mitochondrial metabolism in the heart.

Authors:  Amy K Rines; Hossein Ardehali
Journal:  J Mol Cell Cardiol       Date:  2012-06-02       Impact factor: 5.000

2.  The role of iron, omega-3 Fatty acids, and vitamins in heart failure.

Authors:  Donald S Silverberg; Doron Schwartz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 3.  Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials.

Authors:  Kunal N Bhatt; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2018-06

4.  Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients.

Authors:  Matteo Righini; Vittorio Dalmastri; Irene Capelli; Claudio Orsi; Gabriele Donati; Maria Giovanna Pallotti; Chiara Pedone; Gianni Casella; Pasquale Chieco; Gaetano LA Manna
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 5.  [Iron deficiency : Recognition and treatment].

Authors:  S von Haehling; H Ottenjann; S D Anker
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

6.  Parameters influencing in-hospital mortality in patients hospitalized in intensive cardiac care unit: is there an influence of anemia and iron deficiency?

Authors:  Ewa Uscinska; Bozena Sobkowicz; Robert Sawicki; Izabela Kiluk; Malgorzata Baranicz; Tomasz Stepek; Milena Dabrowska; Maciej Szmitkowski; Wlodzimierz J Musial; Agnieszka M Tycinska
Journal:  Intern Emerg Med       Date:  2014-12-13       Impact factor: 3.397

7.  Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study.

Authors:  Remo Melchio; Gianluca Rinaldi; Elisa Testa; Alessia Giraudo; Cristina Serraino; Christian Bracco; Laura Spadafora; Andrea Falcetta; Stefano Leccardi; Alberto Silvestri; Luigi Fenoglio
Journal:  Intern Emerg Med       Date:  2018-10-01       Impact factor: 3.397

8.  Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.

Authors:  Gema Miñana; Ingrid Cardells; Patricia Palau; Pau Llàcer; Lorenzo Fácila; Luis Almenar; Maria Pilar López-Lereu; Jose V Monmeneu; Martina Amiguet; Jessika González; Alicia Serrano; Vicente Montagud; Raquel López-Vilella; Ernesto Valero; Sergio García-Blas; Vicent Bodí; Rafael de la Espriella-Juan; Juan Sanchis; Francisco J Chorro; Antoni Bayés-Genís; Julio Núñez
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

9.  Iron status in patients with chronic heart failure.

Authors:  Ewa A Jankowska; Jolanta Malyszko; Hossein Ardehali; Ewa Koc-Zorawska; Waldemar Banasiak; Stephan von Haehling; Iain C Macdougall; Guenter Weiss; John J V McMurray; Stefan D Anker; Mihai Gheorghiade; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2012-11-23       Impact factor: 29.983

Review 10.  Iron Therapy in Heart Failure: Ready for Primetime?

Authors:  Ify R Mordi; Aaron Tee; Chim C Lang
Journal:  Card Fail Rev       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.